BRAF-targeted therapy and immune responses to melanoma

Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngiow, Shin Foong, Knight, Deborah A, Ribas, Antoni, McArthur, Grant A, Smyth, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716742/
https://www.ncbi.nlm.nih.gov/pubmed/23894707
http://dx.doi.org/10.4161/onci.24462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716742/
https://www.ncbi.nlm.nih.gov/pubmed/23894707
http://dx.doi.org/10.4161/onci.24462

Ejemplares similares